about
Mucins and toll-like receptors: kith and kin in infection and cancerCancer immunotherapy via dendritic cellsCombining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.Therapeutic Boosting of the Immune Response: Turning to CD14 for Help.Contextualization procedure and modeling of monocyte specific TLR signaling.Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis.Cancer and innate immune system interactions: translational potentials for cancer immunotherapy.TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer.Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironmentSynergy of TLR3 and 7 ligands significantly enhances function of DCs to present inactivated PRRSV antigen through TRIF/MyD88-NF-κB signaling pathway.Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responsesReassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibitionTLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice.The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.Plant-based modulation of Toll-like receptors: an emerging therapeutic model.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.What is and what should always have been: long-lived plasma cells induced by T cell-independent antigens.Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis.Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract.Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia.Toll-like receptors targeting technology for the treatment of lymphoma.CD14 is critical for TLR2-mediated M1 macrophage activation triggered by N-glycan recognition.Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.FC-98 regulates TLR9-mediated of CXCL-10 expression in dendritic cells via MAPK and STAT1 signaling pathway.Biologically relevant doses of mixed aflatoxins B and G up-regulate MyD88, TLR2, TLR4 and CD14 transcripts in human PBMCs.The Immunomodulatory Effect of Bone-Marrow Mesenchymal Stem Cells on Expression of TLR3 and TLR9 in Mice Dendritic CellsRecombinant human annexin A5: a novel drug candidate for treatment of sepsis?Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens.Toll-Like Receptor Ligand-Induced Liver Injury in D-Galactosamine-Sensitized Mice: Differences between TLR7/8 and TLR9 Ligands, Cytokine Patterns, and Cross-Tolerance Induction by TLR2 Ligand Pretreatment.
P2860
Q26830597-312C91A7-8692-4391-B419-1CA4C9AC3FC5Q29615444-2C5431C6-1A9E-4E35-B08C-4152F991A00FQ30358185-199A7D31-F682-49AB-998F-C6317517E89EQ33646535-E83BB28C-2232-4C46-A8CD-1CE3B717BCABQ34510293-AB97D87C-1A60-47BB-8949-E1BCBE9F1A47Q34750515-2A3B8A02-1EEE-42D3-B97F-01A3CF1A8696Q35211600-EA8F509B-F8F3-41B2-87C3-7DE1F66D38C6Q35902972-2B1E3AD9-8CB8-4DD1-9C49-5FE8E4C6BFD1Q35939623-BE83EEB8-B787-4302-AFE4-CE1F0B4F0E5DQ36148314-ECB26685-DAEF-4509-82B0-4E8540BDFFE5Q36758769-C49A12BD-DDD5-4684-9FC4-7B072FD0CC6EQ36764982-1B267124-0E71-43E4-987C-04946B1B03AEQ36879305-971FA33F-403B-4BF8-A504-BBD4348FB608Q36990703-BCC7A075-1361-42A7-A5D6-6FA42EFD80F9Q37210998-34E2200B-018C-46C7-A52F-3AE68378B8C4Q37956385-1410F8D1-374C-4625-A6A8-44A29BC12922Q38040302-A9EEC344-D2E5-4B8F-9F11-9C0B5D52F116Q38059461-CEDA9FE8-D53E-49C1-9C4D-D14A1BAC1AC1Q38066148-58F2A933-77DA-4AB3-839F-A0464BEDD944Q38113207-D0BBCBF3-E2C2-408C-96A8-6A516F517CC2Q38118170-C888C4BB-7133-49E8-AF81-523A73193912Q38453610-FB8C79AF-E01B-4EAC-8829-45616262F323Q38726846-5FC13901-EBC6-438C-BEEE-CAA488CDB971Q38888128-2F7D7C15-5E49-4B31-8FD6-4105A117DD64Q38948266-A65F35D9-EADF-4E54-B195-B2434657DBBBQ40110484-6D2CB12A-0AAB-4CB1-B78E-AC7C8F4CE9C2Q40608326-AEB4691F-7AC4-4DE6-A4D0-A29EBC19EF2BQ42181542-46DC7428-8796-4033-AE94-07822BE9F580Q42258096-82749D40-04D7-4FED-B601-97F0208331F0Q42316872-F1871531-774D-4A87-81CE-BFB100781812Q42337631-BD202259-B7CF-4A58-B2DC-C8628ED1FBA7Q44655068-F13990CC-7ECD-41FB-A19E-CE371D4629B7Q46895698-F613A30C-5E45-4AAE-AA0A-DA6597B0822C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TLR based therapeutics.
@en
TLR based therapeutics.
@nl
type
label
TLR based therapeutics.
@en
TLR based therapeutics.
@nl
prefLabel
TLR based therapeutics.
@en
TLR based therapeutics.
@nl
P1476
TLR based therapeutics.
@en
P2093
Kingston H G Mills
Neil A Marshall
P304
P356
10.1016/J.COPH.2011.03.004
P577
2011-04-16T00:00:00Z